Food and Drug Administration (FDA) has issued a second approvable letter for bazedoxifene, a selective estrogen receptor modulator, for the prevention of postmenopausal osteoporosis.

苯是一种选择性雌激素受体节剂，为预防绝经后骨质疏物。